DocDollars

Karyopharm Therapeutics Inc.

MA · United States · Reporting entity ID 100000806841

Total reported 2019–2025
$57.4M
#156 of 2,960 reporting companies — 0.1% of all reported industry payments
$7.93M in general payments across 29,773 records, plus $49.4M in research funding across 11,041 records.

How it breaks down

General payments $7,933,189
Research funding $49,443,430

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Karyopharm Therapeutics Inc. reported $57.4M to US doctors and teaching hospitals from 2019 to 2025, ranking #156 of 2,960 reporting companies. 86% of that was research funding and 14% general payments such as consulting, speaking, food and travel. 29,773 general payment records and 11,041 research records were filed.

Common questions about Karyopharm Therapeutics Inc.

How much has Karyopharm Therapeutics Inc. paid US doctors?

Karyopharm Therapeutics Inc. reported $57,376,619 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $7,933,189 in general payments, $49,443,430 in research funding.

How does Karyopharm Therapeutics Inc. rank among drug and device companies?

It ranks #156 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Karyopharm Therapeutics Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.